Pharmaceutical composition of arsenic trioxide and FLT3 inhibitor and application of pharmaceutical composition

A technology of arsenic trioxide and inhibitors, applied in the preparation of drugs for the treatment of leukemia, the pharmaceutical composition of arsenic trioxide and FLT3 inhibitors, the application field of drugs, which can solve the problems of poor prognosis

Active Publication Date: 2020-03-31
SHENYANG PHARMA UNIVERSITY
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Patients with FLT3-ITD mutations ha

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of arsenic trioxide and FLT3 inhibitor and application of pharmaceutical composition
  • Pharmaceutical composition of arsenic trioxide and FLT3 inhibitor and application of pharmaceutical composition
  • Pharmaceutical composition of arsenic trioxide and FLT3 inhibitor and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031] The substantive content of the present invention is further described below in conjunction with the implementation examples, but the protection scope of the present invention is not limited thereto.

[0032] Example reagents and methods:

[0033] Cells: AML cells MOLM-13 were purchased from DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig Germany).

[0034] Arsenic trioxide for injection was purchased from Beijing Shuanglu Pharmaceutical Co., Ltd., prepared with water to a storage concentration of 5 mM, and stored at 4°C; venetoclax, midostaurin, sorafenib, gilteritinib, crenolanib, and quizartinib were all purchased from Selleck.

[0035] Method: Accurately weigh venetoclax, midostaurin, sorafenib, gilteritinib, crenolanib, and quizartinib, dissolve them in dimethyl sulfoxide, make 20mM stock solutions, store them at -20°C, and dilute them with culture medium to an appropriate concentration when using . Arsenic trioxide is diluted with w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of biological medicines, and relates to a pharmaceutical composition containing arsenic trioxide (ATO) and an application thereof, in particular to a pharmaceutical composition containing arsenic trioxide and an FLT3 inhibitor and an application of the pharmaceutical composition in preparation of medicines for treating leukemia, in particular to the application of a pharmaceutical composition of arsenic trioxide and an FLT3 inhibitor (midostaurin), sorafenib, gilteritinib, crenolanib or quizartinib in preparation of a medicine for treating AML withFLT3-ITD mutation. Wherein the molar ratio of arsenic trioxide to perindopril to sorafenib to gilteritinib is 100: 1-5: 1, the molar ratio of arsenic trioxide to crenolanib is 100: 1-5: 1, and the molar ratio of arsenic trioxide to quizartinib is 1000: 1-50: 1. The composition disclosed by the invention can selectively induce apoptosis of AML cells subjected to FLT3-ITD mutation, and can be used for treating leukemia.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to a pharmaceutical composition containing arsenic trioxide (ATO) and its application, in particular to a pharmaceutical composition of arsenic trioxide and an FLT3 inhibitor and its application in preparing medicines for treating leukemia. Medications especially involving arsenic trioxide with FLT3 inhibitors (midostaurin, sorafenib, gilteritinib, crenolanib, or quizartinib) Application of the composition in preparation of medicine for treating AML with FLT3-ITD mutation. Background technique [0002] Acute myelogenous leukemia (AML) is a malignant hematological tumor, and multiple chromosomal and gene mutations interact in patients, resulting in a high degree of heterogeneity in the disease. The traditional therapy for AML is combined chemotherapy with cytarabine and daunorubicin, which can achieve 35%-40% remission in young AML patients, but the 5-year remission rate in elderly...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K33/36A61P35/02A61K31/553A61K31/44A61K31/497A61K31/4709A61K31/5377
CPCA61K45/06A61K33/36A61K31/553A61K31/44A61K31/497A61K31/4709A61K31/5377A61P35/02A61K2300/00
Inventor 景永奎李盈
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap